Sector News

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

January 15, 2022
Life sciences

Through a spate of dealmaking over the past few years, Sanofi has made its intentions in the gene and cell therapy field clear. The company seems uninterested in hard-to-manufacture treatments that consist of individual patient cells genetically modified outside the body, instead favoring ones meant to be used “off the shelf.”

In 2020, for instance, the French drugmaker bought Kiadis Pharma, which is working on more convenient cell treatments for cancer. Sanofi acquired another off-the-shelf cell therapy developer, Tidal Therapeutics, the following year, and envisions its recent investments in messenger RNA technology as aiding in the effort.

In doing so, Sanofi isn’t just bypassing the first generation of so-called CAR-T therapies, which are powerful tools against certain blood cancers but are limited by their complexity. It’s also casting aside outside-the-body treatments for genetic diseases, a class that includes drugs from CRISPR Therapeutics and Bluebird bio that have shown considerable promise treating blood diseases like beta thalassemia and sickle cell. READ MORE

By Ben Fidler

Source: biopharmadive.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach